comparemela.com

Latest Breaking News On - Peterl hoang - Page 2 : comparemela.com

Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment

Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment Financialnewsmedia.com News Commentary Share this article Share this article PALM BEACH,  Fla., May 20, 2021 /PRNewswire/ Sadly, for patients, the pancreatic cancer market has been steadily rising over the past several years and will most likely continue to grow over the next couple of years. Revenues will increase but so will money flow into R&D efforts to treat this condition. Pancreatic cancer is one of the most dangerous malignancies and is the fourth most common cause of cancer deaths in the U.S.  Increasing tobacco consumption, smoking, obesity, and growing awareness pertaining to various treatment options available are propelling the market growth at a global level. The peak incidence of pancreatic cancer is seen in the age group of 65 to 75 years. Thus, growing geriatric population is also expected to drive the growth during the forecast period. Furthermore, pancreatic cancer is ex

Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results

Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results Marker continues to advance Phase 2 AML trial, recently dosing first patient Company closed financing extending cash runway into Q1 2023 Company to host conference call and webcast today at 5:00 p.m. ET News provided by Share this article Share this article HOUSTON, May 12, 2021 /PRNewswire/ Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the first quarter ended March 31, 2021.   We had a productive first quarter supported by our recently completed financing, strengthening our overall cash position and enabling continued growth and expansion of our Multi-TAA pipeline, said Peter L. Hoang, President & CEO of Marker Therapeutics. In add

Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results

Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results - Dosed first patient in the Company s Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate, for the treatment of post-transplant acute myeloid leukemia - - Completed construction of new in-house cGMP manufacturing facility in Houston to supply MultiTAA-specific T cell products, including MT-401, for clinical activities and potential commercialization; facility expected to be fully operational in 1H 2021 - News provided by Share this article Share this article HOUSTON, March 9, 2021 /PRNewswire/  Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the fiscal year ended December 31, 2020.  

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.